Trial Portfolio for UNC Multiple Myeloma

Multiple Myeloma

Frontline	Post-transplant/maintenance	Relapsed/ Refractory		
		1+ prior lines	2+ prior lines	3+ prior lines
Currently open				
LCCC 1944: Isatuximab + Lenalidomide + Dexamethasone in older/frail patients with newly diagnosed MM [Phase 2]	**S1803:** Phase III study of daratumumab/rHuPH20 (NSC-810307) + lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapy in patients with MM using minimal residual disease to direct therapy duration (Drammatic Study)	**64407564MMY3002:** Talq-Dara-PD vs Dara-PD for 1+ prior lines of therapy		
		No trials in development	No trials in development	**GSK-209626-DREAMM12 (Part 2):** A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12) **LCCC 1603: anti-CD138 CAR-T for R/R myeloma (Run out of CT group)** **M24-108:** Subject must have a confirmed diagnosis of R/R MM with documented evidence of progression during or after the subject's last treatment regimen. Subject must have received at least 3 or more lines of therapy, including a PI, an IMiD, and an anti-CD38 monoclonal antibody. Subject must have never received BCMA-targeted therapy. Subject has no known central nervous system involvement MM.
No trials in development		No trials in development	No trials in development	**R5458-ONC-2012:** Subject must have RRMM with progression following at least 3 lines of therapy, or at least 2 lines of therapy and either prior exposure to at least 1 anti-CD38 antibody, 1 immunomodulatory imide drug (IMiD) and 1 proteasome inhibitor (PI), or double-refractory to 1 PI and 1 IMiD, or the combination of 1 PI and 1 IMiD.
		LCCC 2119 (SGZ-2020-13220): Isatuximab plus pomalidomide and dexamethasone in highly toxicity-vulnerable subjects with relapsed or refractory multipe myeloma		
		IS8 2001-101: Participants with pathologically confirmed MM with measurable M-protein, ECOG performance status score of 2 or less, prior treatment with IMiDs, proteasome inhibitors, and anti-CD38 therapies either in combination or as a single agent.		
		ACCRU-MY-1901: Open Label, Phase 2, Single-Arm Study of Selinexor, Daratumumab, Carfilzomib and Dexamethasone for High-Risk, Relapsed and Relapsed/Refractory Multiple Myeloma Patients Who Have Received 1 – 3 Prior Lines of Therapy		
Pending/ In Development/ Coming Soon				
No trials in development	**In Activation: A062102-CIRB:** Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients	**In Activation: M22-574:** A Phase 3, Multicenter, Randomized, Open-Label Study of ABBV-383 Compared with Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)		
No trials in development	**No trials in development**	**No trials in development**		

Smoldering Myeloma

Frontline	Post-transplant maintenance	Relapsed/ Refractory		
		1+ prior lines	2+ prior lines	3+ prior lines
Currently open				
EAA173: Dara + Len in Smoldering Myeloma [Phase 3]	**No trials available**	**No trials available**	**No trials available**	**No trials available**
Pending/ In Development/ Coming Soon				
No trials in development	**No trials in development**	**No trials in development**	**No trials in development**	**No trials in development**

Amyloidosis

Frontline	Post-transplant maintenance	Relapsed/ Refractory		
		1+ prior lines	2+ prior lines	3+ prior lines
Currently open				
No trials available	**No trials available**	**In Activation: NCI-10440-CIRB: A Phase 1/1a Study of Venetoclax, MLN9708 (ixazomib citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis**		
Pending/ In Development/ Coming Soon				
No trials in development	**No trials in development**	**No trials in development**		

Other MGRS

Frontline	Post-transplant maintenance	Relapsed/ Refractory		
		1+ prior lines	2+ prior lines	3+ prior lines
Currently open				
No trials available	**No trials available**	**No trials available**	**No trials available**	**No trials available**
Pending/ In Development/ Coming Soon				
In Activation: MSK 22-424: A Phase II Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab for Patients with Monoclonal Gammopathy of Renal Significance (MGRS)	**No trials in development**	**No trials in development**	**No trials in development**	**No trials in development**

TSHS Trials

TSHS Coordinators
Nick_Mangieri@med.unc.edu
Kendall_Conder@med.unc.edu

TSHS Manager
Julianna_Macatrone@med.unc.edu

LCCC 1728: Plasma cell disorder registry
PI: Dr. Sascha Tuchman; Coordinator: Nick Mangieri/Kendall Conder
Open to Accrual

LCCC 1849 (PERMIT):
PI: Dr. Eben Lichtman; Coordinator: Nick Mangieri/Kendall Conder
Open to Accrual

Patient Discovery: Patient Appointment Companion (PAC) in amyloidosis and multiple myeloma
PI: Dr. Sascha Tuchman; Coordinator: Nick Mangieri
Closed to Accrual

Halo: A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusion-related Reations in Participants Treated with Daratumumab (intravenous or Subcutaneous)
PI: Sam Rubinstein Coordinator: Kendall Conder
Open to Accrual

Screening for AL Amyloidosis in Smoldering Multiple Myeloma (Save 2.0)
PI: Sascha Tuchman
New